A new study by the Centers for Medicare & Medicaid Services (CMS) found that prices available from Medicare-Approved Drug Discount Cards are lower than current Internet and mail-order pharmacy prices. In particular, the CMS analysis showed that t
Vertex Pharmaceuticals Incorporated has announced that it has expanded its drug discovery and development collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit drug discovery and developme
Spectrum Pharmaceuticals, Inc has announced that new data on pre-clinical activity of satraplatin in prostate cancer cell lines are being presented at the 95th Annual Meeting of the American Asso
A small clinical trial of patients with multiple sclerosis (MS) who did not respond to interferon alone found that adding the human antibody daclizumab improved patient outcome. Patients who received the combined therapy had a 78 percent reduction in ne
Not everybody can safely be vaccinated against smallpox using the current FDA-approved vaccine. Scientists hope another study vaccine, now undergoing its first testing in the United States at Saint Louis University, will g
Almost half of all medicines globally are used irrationally. This, say medicines experts at the World Health Organization (WHO), can have severe consequences: adverse drug reactions, drug resistance, protracted illness and even d
Serono, Inc., the US affiliate of Serono, announced today the launch of Zorbtive? [somatropin (rDNA origin) for injection] for use in the treatment of patients with short bowel syndrome.
Health Canada is warning consumers not to use Bell Magnum Bullet capsules, after it was found to contain an unauthorized substance similar, but not identical to, tadalafil. Tadalafil is a prescription drug approved for male erectile dysfunction, sold under
America's leading scientific organization investigating the risks that mercury-containing medical products pose to our children-has posted the results of an investigative analysis of several authors relied upon for the flawed Institute of Medicine (IOM)
ALTANA AG's investigational anti-inflammatory medicine roflumilast improved lung function in patients with Chronic Obstructive Pulmonary Disease (COPD) according to a placebo controlled study presented at the annual meeti
Atrix Laboratories, Inc. has announced today that the company has signed a limited feasibility agreement with Aventis SA (NYSE: AVE) to begin preliminary research on two proprietary Aventis compounds formulated in Atrix's delivery technology, Atrigel?. The current agreement is specific for these compounds in an undisclosed therapeutic area.
"We are pleased that Aventis chose Atrix for this innovative development initiative," said David R. Bethune, Atrix's chairman and chief executive officer. "We believe our Atrigel drug delivery technology brings several advantages in sustained release to these challenging compounds."
Atrix Laboratories, Inc. is an emerging specialty pharmaceutical company focused on advanced drug delivery. With unique extended release and topical technologies, Atrix is currently developing a diverse portfolio of proprietary products, including oncology, pain management, and dermatology products. The company also partners with large pharmaceutical and biotechnology companies to apply its proprietary technologies to new chemical entities or to extend the patent life of existing products.